New drug combo enters human testing for Tough-to-Treat cancers

NCT ID NCT05544929

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to find a safe dose of a new drug called KFA115, both by itself and combined with an existing immunotherapy (pembrolizumab). It involves about 126 adults with various advanced cancers that have stopped responding to standard treatments. The main goal is to understand the side effects and determine the best dose for future research.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Massachusetts General Hospital .

Boston, Massachusetts, 02114, United States
NYU School of Medicine

New York, New York, 10015, United States
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.

ANAL CANCER CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, OVARIAN EPITHELIAL CARCINOMA, RENAL CELL CARCINOMA, THYMIC CUTANEOUS MELANOMA ESOPHAGOGASTRIC CANCER HIGH MICROSATELLITE INSTABILITY COLORECTAL CARCINOMA MESOTHELIOMA NASOPHARYNGEAL CARCINOMA SQUAMOUS CELL CARCINOMA OF HEAD AND NECK TRIPLE NEGATIVE BREAST NEOPLASMS